A naukri.com initiative
Unite
7d
178
Image Credit: Unite
Biostate AI Raises $12M Series A to Train the ChatGPT of Molecular Medicine
- Biostate AI, a molecular diagnostics startup, raised $12 million in a Series A funding round led by Accel, with participation from other investors and high-profile angels.
- The company aims to make biology predictable, leveraging generative AI to unlock precision medicine on a large scale.
- Biostate employs a Netflix-like model, using RNA sequencing and generative AI to analyze data, improve models, and gain clinical insights.
- Through technologies like BIRT and PERD, Biostate reduces costs and addresses variability in sequencing.
- Their proprietary foundation model, Biobase, is trained on diverse transcriptomic profiles to understand gene expression patterns in health and disease.
- Biostate's Prognosis AI shows promise in leukemia relapse forecasting and is being piloted for multiple sclerosis prediction.
- By scaling RNA sequencing and utilizing GenAI tools, Biostate aims to build the largest RNAseq dataset for disease understanding and treatment guidance.
- The company envisions developing a general-purpose AI for all diseases, moving towards predictive and personalized medicine.
- Biostate plans to advance clinical collaborations in oncology, cardiovascular disease, and immunology, focusing on regulatory validation and commercial expansion.
- Their goal is to create an AI model trained on human biology to revolutionize precision medicine through prediction and personalization.
- With a funding of over $20 million and growing partnerships, Biostate is poised to shape the future of healthcare with AI-driven diagnostics.
Read Full Article
10 Likes
For uninterrupted reading, download the app